Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system

• Auteurs principaux: Tingting Jiang (Auteur), Hui Su (Auteur), Yanping Li (Auteur), Yuanlin Wu (Auteur), Yue Ming (Auteur), Chen Li (Auteur), Ruoqiu Fu (Auteur), Lu Feng (Auteur), Ziwei Li (Auteur), Li Li (Auteur), Rui Ni (Auteur), Yao Liu (Auteur)
• Format: Livre
• Publié: Frontiers Media S.A., 2022-12-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Objective: In recent years, the emergence of immunomodulatory drugs (IMiDs) has significantly improved clinical outcomes in patients with multiple myeloma (MM); however, serious adverse events (AEs) have hindered their safe clinical application. This study aimed to characterize the safety profiles a...